Genzyme’s Lumizyme REMS Eliminated Due To Expanded Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves Lumizyme for all Pompe disease patients, making it unnecessary to restrict use to a specific age group; Myozyme, produced at a different scale, will remain available.
You may also be interested in...
When To End A REMS? Soliris Review Stirs Debate On How To Scale Back
Risk management program for Alexion’s orphan drug eculizumab appears to be succeeding, but what does FDA need to see to make it less burdensome?
GSK’s Promacta Adds ‘Breakthrough’ Claim On Strength Of Small NIH Study
Supplemental approval for severe aplastic anemia, a “breakthrough” designation, was based on a single-center, open-label Phase II trial in 43 patients that was conducted by the National Heart, Lung and Blood Institute.
FDAAA Fading? REMS Use Continues To Decline As Drug Safety Law Matures
FDA’s use of REMS continues to fall to almost undetectable levels, with the agency using the safety tools just a handful of times in the sixth full year of the program. REMS are now very much the exception and not the rule for new products – but still a very important exception.